What is the initial management and treatment approach for a patient presenting with hypercalcemia?

Hypercalcemia Workup and Management

Initial Diagnostic Evaluation

The diagnostic workup for hypercalcemia should begin with measuring serum calcium (corrected for albumin), intact parathyroid hormone (iPTH), parathyroid hormone-related protein (PTHrP), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, phosphorus, magnesium, albumin, and renal function (creatinine, BUN). 1, 2, 3

Calculate Corrected Calcium

• Use the formula: Corrected calcium (mg/dL) = Total calcium (mg/dL) + 0.8 × (4.0 - serum albumin g/dL) 3, 4
• Alternatively, measure ionized calcium directly if available 5

Classify Severity

• Mild: Total calcium <12 mg/dL or ionized calcium 5.6-8.0 mg/dL (1.4-2 mmol/L) 5
• Moderate: Total calcium 12-13.5 mg/dL 1, 4
• Severe: Total calcium >13.5 mg/dL (>14 mg/dL) or ionized calcium ≥10 mg/dL (≥2.5 mmol/L) 1, 5

Assess Clinical Symptoms

• Mild/moderate: Polyuria, polydipsia, nausea, confusion, vomiting, abdominal pain, myalgia, fatigue, constipation 1, 5
• Severe: Mental status changes, bradycardia, hypotension, dehydration, acute renal failure, somnolence, coma 1, 5

Determine Etiology Based on PTH Level

PTH is the single most important test to differentiate causes of hypercalcemia. 5, 6

PTH-Dependent (Elevated or Inappropriately Normal PTH)

• Primary hyperparathyroidism (accounts for ~90% of outpatient hypercalcemia with malignancy) 5, 6
• Characterized by elevated iPTH with elevated calcitriol levels 1

PTH-Independent (Suppressed PTH <20 pg/mL)

• Malignancy-associated hypercalcemia (most common in hospitalized patients) 1, 5
  • PTHrP-mediated: Suppressed iPTH, low/normal calcitriol, elevated PTHrP (squamous cell lung cancer, renal cell carcinoma) 1, 7
  • Osteolytic: Direct bone destruction from metastases 1
  • 1,25-dihydroxyvitamin D-mediated: Lymphomas 1
• Granulomatous diseases (sarcoidosis): Elevated 1,25-dihydroxyvitamin D 1, 7
• Vitamin D intoxication: Elevated 25-hydroxyvitamin D 1, 7
• Medications: Thiazide diuretics, calcium/vitamin D supplements, lithium 7, 5

---

Treatment Algorithm

Step 1: Immediate Management - Hydration

All patients with moderate to severe hypercalcemia require aggressive IV normal saline hydration as the first intervention. 1, 2, 3

• Administer IV 0.9% normal saline to correct hypovolemia and promote calciuresis 1, 2
• Target urine output: 100-150 mL/hour (or 3 mL/kg/hour in children <10 kg) 1, 2, 3
• Avoid overhydration in patients with cardiac or renal failure 4
• Loop diuretics (furosemide) should only be used after volume repletion to prevent fluid overload in patients with renal or cardiac insufficiency—not for calciuresis 1, 2, 6

Step 2: Definitive Pharmacologic Treatment

For Moderate to Severe Hypercalcemia (Especially Malignancy-Associated)

Bisphosphonates are the cornerstone of treatment and should be administered after initiating hydration. 1, 2, 3

Zoledronic acid is superior to pamidronate and is the preferred bisphosphonate. 1, 2, 5

• Zoledronic acid: 4 mg IV infused over at least 15 minutes (not 5 minutes as in older studies) 1, 2

  • Normalizes calcium in 50% of patients by day 4 (vs. 33% with pamidronate) 1
  • Reserve 8 mg dose for relapsed or refractory cases 1
  • Adjust dose for renal impairment; monitor serum creatinine before each dose 1, 2

• Pamidronate: 60-90 mg IV over 2-24 hours (longer infusions reduce renal toxicity) 1, 4

  • 60-90 mg for moderate hypercalcemia (corrected calcium 12-13.5 mg/dL) 4
  • 90 mg for severe hypercalcemia (corrected calcium >13.5 mg/dL) 4

Critical monitoring: Withhold bisphosphonates if renal deterioration occurs (creatinine increase ≥0.5 mg/dL from normal baseline or ≥1.0 mg/dL from abnormal baseline) 1, 2

For Immediate Short-Term Control (Bridge Therapy)

Calcitonin provides rapid onset (within hours) but limited duration due to tachyphylaxis. 1, 2, 6

• Calcitonin-salmon: 4 IU/kg subcutaneously or intramuscularly every 12 hours, or 200 IU/day intranasal 2, 6
• Use as bridge therapy while waiting for bisphosphonates to take effect (bisphosphonates require 2-4 days) 2, 6
• Tachyphylaxis develops within 48-72 hours, limiting long-term use 6, 8

For Vitamin D-Mediated Hypercalcemia

Glucocorticoids are the primary treatment for hypercalcemia due to excessive intestinal calcium absorption. 1, 2, 7, 5

• Indications: Vitamin D intoxication, granulomatous diseases (sarcoidosis), lymphomas, multiple myeloma 1, 2, 7
• Mechanism: Reduce 1,25-dihydroxyvitamin D production and intestinal calcium absorption 1, 6

For Refractory Hypercalcemia

Denosumab (120 mg subcutaneously) is FDA-approved for bisphosphonate-refractory hypercalcemia of malignancy. 1, 2, 5

• Lowers serum calcium in 64% of patients within 10 days 1
• Higher risk of hypocalcemia compared to zoledronic acid; monitor calcium closely and provide calcium/vitamin D supplementation 1, 2
• Preferred in patients with renal impairment 2, 5

Step 3: Renal Failure Management

For severe hypercalcemia with renal failure not responsive to hydration, dialysis with calcium-free or low-calcium solution is indicated. 1, 2, 6

• Hemodialysis effectively removes calcium through diffusive therapy 1, 2
• Consider denosumab over bisphosphonates in patients with significant renal impairment 2, 5

Step 4: Treat Underlying Cause

Definitive treatment requires addressing the underlying etiology. 3, 7, 5

• Primary hyperparathyroidism: Parathyroidectomy for symptomatic patients, those with osteoporosis, impaired kidney function, kidney stones, age <50 years, or calcium >1 mg/dL above upper limit of normal 7, 5
• Malignancy: Treat underlying cancer; median survival after hypercalcemia discovery in lung cancer is ~1 month 1
• Granulomatous disease: Glucocorticoids 1, 7

---

Special Populations and Considerations

Multiple Myeloma

• Hydration + bisphosphonates (zoledronic acid 4 mg IV monthly preferred) + glucocorticoids 1, 2
• Continue bisphosphonates for up to 2 years 2
• Ensure adequate hydration before treatment in patients with Bence-Jones proteinuria 1

Pediatric Patients (Williams Syndrome)

• Low-calcium diet and increased water intake under medical supervision 1, 3, 7
• Monitor serum calcium every 4-6 months until age 2, then every 2 years 1
• Avoid vitamin D supplements in early childhood 1, 2, 3, 7

Asymptomatic Mild Hypercalcemia

• Oral hydration may be sufficient 1, 5
• Observation appropriate for patients >50 years with calcium <1 mg/dL above upper limit and no skeletal/kidney disease 5

---

Critical Pitfalls to Avoid

• Do not use loop diuretics before adequate volume repletion—this worsens dehydration and hypercalcemia 6
• Avoid NSAIDs and IV contrast in patients with renal impairment—these worsen kidney function 2, 3
• Do not restrict calcium intake without medical supervision in normocalcemic patients 1, 3
• Monitor for bisphosphonate-related complications: Renal toxicity (monitor creatinine before each dose), osteonecrosis of jaw, hypocalcemia 1, 2, 3
• Avoid vitamin D supplements in hypercalcemic patients, particularly children 1, 2, 3, 7
• Do not delay bisphosphonates in moderate-severe hypercalcemia—temporary measures provide only 1-4 hours of benefit 2
• Correct hypocalcemia before initiating bisphosphonates; monitor calcium closely with denosumab (higher hypocalcemia risk) 2
• Allow minimum 7 days before retreatment with bisphosphonates to assess full response 4

---

Monitoring and Follow-Up

• Monitor serum calcium, renal function (creatinine, BUN), electrolytes, and albumin regularly 1, 2, 3, 7
• Assess urine calcium/creatinine ratio if hypercalciuria suspected 1
• Perform renal ultrasonography if nephrocalcinosis suspected 1
• ECG monitoring for QT interval changes in severe hypercalcemia 2